Payment overview · 2025
General Payments
$8,472.51
112 reported records · 22 companies
Healthcare provider profile · identity verified
Kalyan Kumar Veerina, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Cardiovascular Disease · OPELOUSAS, LA · NPI 1619974557
Verified facts
What the public records show
CMS Open Payments records show Kalyan Kumar Veerina, MD received $8,472.51 in general payments during 2025 across 112 reported records.
Imperative Care, Inc accounted for 34.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 43 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 396 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 155 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Imperative Care, Inc | Unresolved — no canonical attribution shown | $2,889.19 | 34.1% | 25 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $2,400.00 | 28.3% | 1 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $695.66 | 8.2% | 8 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $421.89 | 5.0% | 12 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$318.74 | 3.8% | 7 | 2025 |
| Penumbra, Inc. | Unresolved — no canonical attribution shown | $235.20 | 2.8% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $234.29 | 2.8% | 11 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $212.75 | 2.5% | 7 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $205.56 | 2.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $192.32 | 2.3% | 11 | 2025 |
| Tactile Systems Technology Inc | Unresolved — no canonical attribution shown | $156.59 | 1.9% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $152.72 | 1.8% | 11 | 2025 |
| Contego Medical, Inc | Unresolved — no canonical attribution shown | $121.28 | 1.4% | 1 | 2025 |
| Bard Peripheral Vascular, Inc. | Unresolved — no canonical attribution shown | $76.68 | 0.9% | 3 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $32.67 | 0.4% | 2 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $27.75 | 0.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $18.97 | 0.2% | 1 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $18.68 | 0.2% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $17.20 | 0.2% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $15.82 | 0.2% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $15.29 | 0.2% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $13.26 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $4,722.51 | 110 |
| Long term medical supply or device loan | $2,400.00 | 1 |
| Consulting Fee | $1,350.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VenaCure 1470 Pro Normalized: venacure 1470 pro |
Device | AngioDynamics, Inc. | $2,400.00 | 1 | 2025 |
Source payment records
|
|||||
| SYMPHONY CATHETER Normalized: symphony catheter |
Device | Imperative Care, Inc | $1,431.69 | 22 | 2025 |
Source payment records
|
|||||
| ZOOM 88-T LARGE DISTAL PLATFORM Normalized: zoom 88 t large distal platform |
Device | Imperative Care, Inc | $1,350.00 | 1 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $695.66 | 8 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $421.89 | 12 | 2025 |
Source payment records
|
|||||
| Indigo System Normalized: indigo system |
Device | Penumbra, Inc. | $235.20 | 2 | 2025 |
Source payment records
|
|||||
| RotarexS 6 F x 135 cm Normalized: rotarexs 6 f x 135 cm |
Device | Becton, Dickinson and Company | $205.56 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $160.02 | 4 | 2025 |
Source payment records
|
|||||
| IN.PACT ADMIRAL Normalized: in pact admiral |
Device | Medtronic, Inc. | $159.50 | 2 | 2025 |
Source payment records
|
|||||
| Flexitouch Plus Normalized: flexitouch plus |
Device | Tactile Systems Technology Inc | $156.59 | 2 | 2025 |
Source payment records
|
|||||
| Nimbl Normalized: nimbl |
Device | Tactile Systems Technology Inc | $156.59 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $150.75 | 10 | 2025 |
Source payment records
|
|||||
| PRODIGY CATHETER Normalized: prodigy catheter |
Device | Imperative Care, Inc | $107.50 | 2 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROGLIDE Normalized: perclose proglide |
Device | Abbott Laboratories | $79.53 | 1 | 2025 |
Source payment records
|
|||||
| Venovo Normalized: venovo |
Device | Bard Peripheral Vascular, Inc. | $76.68 | 3 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $67.62 | 1 | 2025 |
Source payment records
|
|||||
| ESPRIT Normalized: esprit |
Device | Abbott Laboratories | $53.30 | 4 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.73 | 3 | 2025 |
Source payment records
|
|||||
| CHOCOLATE PTA BALLOON CATHETER Normalized: chocolate pta balloon catheter |
Device | Medtronic, Inc. | $45.48 | 1 | 2025 |
Source payment records
|
|||||
| LUX-Dx Insertable Cardiac Monitor Normalized: lux dx insertable cardiac monitor |
Device | Boston Scientific Corporation | $42.80 | 2 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK PERIPHERAL Normalized: diamondback peripheral |
Device | Abbott Laboratories | $35.11 | 2 | 2025 |
Source payment records
|
|||||
| ELUVIA Normalized: eluvia |
Device | Boston Scientific Corporation | $34.53 | 3 | 2025 |
Source payment records
|
|||||
| PERCLOSE PROSTYLE Normalized: perclose prostyle |
Device | Abbott Laboratories | $33.30 | 2 | 2025 |
Source payment records
|
|||||
| XACT Normalized: xact |
Device | Abbott Laboratories | $33.05 | 2 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $32.67 | 2 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $27.75 | 1 | 2025 |
Source payment records
|
|||||
| CLOSUREFAST Normalized: closurefast |
Device | Medtronic, Inc. | $25.68 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $23.30 | 1 | 2025 |
Source payment records
|
|||||
| ACCOLADE SR Normalized: accolade sr |
Device | Boston Scientific Corporation | $21.97 | 1 | 2025 |
Source payment records
|
|||||
| Ranger Normalized: ranger |
Device | Boston Scientific Corporation | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| myLUX Patient Kit with mobile device Normalized: mylux patient kit with mobile device |
Device | Boston Scientific Corporation | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| EkoSonic Normalized: ekosonic |
Device | Boston Scientific Corporation | $17.22 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $15.82 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.60 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| AngioJet Ultra 5000A Normalized: angiojet ultra 5000a |
Device | Boston Scientific Corporation | $14.81 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $13.26 | 1 | 2025 |
Source payment records
|
|||||
| ABRE Normalized: abre |
Device | Medtronic, Inc. | $11.59 | 1 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $8.87 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $1.97 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 396 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 155 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
396 | 68 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
155 | 26 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 1506 | 322 |
| Amlodipine Besylate | Amlodipine Besylate | 810 | 176 |
| Atorvastatin Calcium | Atorvastatin Calcium | 789 | 183 |
| Metoprolol Succinate | Metoprolol Succinate | 690 | 139 |
| Furosemide | Furosemide | 660 | 159 |
| Carvedilol | Carvedilol | 471 | 97 |
| Xarelto | Rivaroxaban | 456 | 79 |
| Eliquis | Apixaban | 396 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 323 | 72 |
| Ranolazine Er | Ranolazine | 282 | 48 |
| Hydrochlorothiazide | Hydrochlorothiazide | 275 | 65 |
| Lisinopril | Lisinopril | 275 | 51 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 260 | 55 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 255 | 49 |
| Potassium Chloride | Potassium Chloride | 245 | 49 |
| Losartan Potassium | Losartan Potassium | 239 | 57 |
| Pravastatin Sodium | Pravastatin Sodium | 217 | 39 |
| Clonidine Hcl | Clonidine Hcl | 182 | 45 |
| Nebivolol Hcl | Nebivolol Hcl | 173 | 41 |
| Entresto | Sacubitril/Valsartan | 155 | 26 |
| Nitroglycerin | Nitroglycerin | 152 | 79 |
| Cilostazol | Cilostazol | 150 | 23 |
| Simvastatin | Simvastatin | 136 | 30 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 129 | 26 |
| Hydralazine Hcl | Hydralazine Hcl | 126 | 27 |
| Valsartan | Valsartan | 116 | 28 |
| Sotalol | Sotalol Hcl | 88 | 16 |
| Benazepril Hcl | Benazepril Hcl | 86 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 81 | 16 |
| Pantoprazole Sodium | Pantoprazole Sodium | 79 | 17 |
| Warfarin Sodium | Warfarin Sodium | 77 | 20 |
| Gabapentin | Gabapentin | 69 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 66 | suppressed |
| Digoxin | Digoxin | 66 | 11 |
| Ezetimibe | Ezetimibe | 64 | 15 |
| Metolazone | Metolazone | 64 | 16 |
| Spironolactone | Spironolactone | 55 | 11 |
| Irbesartan | Irbesartan | 53 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 51 | 14 |
| Lovastatin | Lovastatin | 49 | 11 |
| Nifedipine Er | Nifedipine | 47 | 15 |
| Diazepam | Diazepam | 46 | 33 |
| Repatha Sureclick | Evolocumab | 42 | suppressed |
| Fenofibrate | Fenofibrate | 38 | suppressed |
| Torsemide | Torsemide | 37 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 34 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 28 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 25 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 24 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 23 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 22 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 21 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 21 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 20 | suppressed |
| Vascepa | Icosapent Ethyl | 20 | suppressed |
| Atenolol | Atenolol | 18 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 18 | suppressed |
| Omeprazole | Omeprazole | 18 | suppressed |
| Mounjaro | Tirzepatide | 17 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Praluent Pen | Alirocumab | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Prednisone | Prednisone | 14 | 11 |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $8,472.51 · 112 records | Imperative Care, Inc | ABRE, ACCOLADE SR, AREXVY, AngioJet Ultra 5000A, Assure WCD, CHOCOLATE PTA BALLOON CATHETER, CLOSUREFAST, DIAMONDBACK PERIPHERAL, ELIQUIS, ELUVIA, ENTRESTO, ESPRIT, EkoSonic, FUROSCIX, Flexitouch Plus, IN.PACT ADMIRAL, INSPIRE, Indigo System, Kerendia, LEQVIO, LUX-Dx Insertable Cardiac Monitor, LifeVest, MICRA, Nimbl, Ozempic, PERCLOSE PROGLIDE, PERCLOSE PROSTYLE, PRODIGY CATHETER, Ranger, RotarexS 6 F x 135 cm, Rybelsus, SHINGRIX, SYMPHONY CATHETER, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, UPTRAVI, VenaCure 1470 Pro, Venovo, WATCHMAN FLX, Wegovy, XACT, ZOOM 88-T LARGE DISTAL PLATFORM, myLUX Patient Kit with mobile device | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error